The subcutaneous injection: Herceptin Hylecta of the star drug Herceptin under Roche has recently been approved by FDA for: a. HER2-positive early breast cancer in combination with chemotherapy; b. HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. This approval will strengthen the anti-cancer effects of Herceptin, and means another advancement of Herceptin. Since first approved in 1998, Herceptin has been very excellent over the two decades, continued to “seize territory”, and received wide recognition, with sales on the rise! Next, let’s see the glorious development road of the drug.
